2008 JASN IMPACT FACTOR 7.505	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) All Versions of this Article: ASN.2008070786v1 21/1/14    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Jayne, D. PubMed PubMed Citation Articles by Jayne, D.

Role of Rituximab Therapy in Glomerulonephritis

Renal Medicine, Addenbrooke's Hospital, Cambridge, United Kingdom

Correspondence: Dr. David Jayne, Box 118, Vasculitis and Lupus Office, Renal Medicine, Addenbrooke's Hospital, Hills Road, Cambridge, CB2 2QQ, UK. Phone: +44-01223-217259; Fax: +44-0-1223-586796; E-mail: dj106{at}cam.ac.uk

B cell depletion with the monoclonal antibody rituximab is attracting increasing attention in systemic lupus erythematosus, vasculitis, and primary glomerulonephritis. Existing, uncontrolled data report high response rates in patients with refractory disease. If supported by the results of ongoing randomized trials, then rituximab and related B cell–depleting or –modulating drugs are likely to become a component in the future management of these disorders. Their use may improve patient outcomes by permitting more complete disease control and reduced exposure to glucocorticoid and traditional immunosuppressive drugs. The toxicity and infective risk of B cell–targeted agents in renal disease needs to be determined as well as their optimal dosing in combination with conventional agents.

Copyright © 2009 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673